Drugmaker Novo Nordisk will have its weight-loss drugs, including Ozempic, Saxenda and Wegovy, investigated after Iceland’s health regulator flagged three cases of patients reporting suicidal thoughts.
The European Medicines Agency —the EU’s pharmaceutical supervisory branch—is probing the creator of popular diabetes and weight-loss drug Ozempic.
But the Danish drugmaker said in athat it hasn’t seen a “causal association” between the active ingredients in the drugs and “suicidal and self-harming thoughts.” Novo Nordisk rose to prominence after the viral success of Ozempic, which has become so popular as a weight loss solution that there was a
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
EU probes Ozempic, weight-loss drug Saxenda after reports of suicidal thoughtsThe European Medicines Agency (EMA) is investigating Novo Nordisk's diabetes drug Ozempic and weight-loss treatment Saxenda after Iceland's health regulator flagged three cases of patients thinking about suicide or self-harm.
続きを読む »
EU Investigates Ozempic Maker After Reports Of Suicidal ThoughtsThe Danish pharma giant finds itself under scrutiny once again- this time, from European regulators.
続きを読む »
Europe Is Probing Whether Ozempic Use Raises Risk of Suicidal ThoughtsEuropean drug regulators are reviewing the risk of thoughts of suicide and self-harm in people taking Ozempic and another weight-loss drug after getting three reports
続きを読む »
Popular weight loss drug gets new warningWegovy and Ozempic are brand names for a drug called semaglutide.
続きを読む »
Woman dies in East County house fire, deputies investigatingThe medical examiner's office is working to make a positive ID of the woman and find out the cause of her death.
続きを読む »